Ribbon Health vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 35)
Ribbon Health logo

Ribbon Health

EmergingHealthTech

Provider Data API

Ribbon Health provides an API for accurate, real-time provider data — physician directories, insurance acceptance, and location details — helping health plans and apps build reliable care navigation.

AI VisibilityBeta
Overall Score
D35
Category Rank
#543 of 596
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
38
Gemini
40

About

Ribbon Health aggregates and continuously cleans provider data — physician names, specialties, practice locations, insurance plans accepted, and availability — and delivers it through an API that health technology companies, payers, and health systems use to build accurate provider directories and care navigation tools. The core problem Ribbon solves is that provider data decays rapidly as doctors change practices, update insurance contracts, and open or close locations, making directory accuracy a persistent challenge across the industry.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

35
Overall Score
81
#543
Category Rank
#17
82
AI Consensus
71
stable
Trend
stable
39
ChatGPT
80
38
Perplexity
75
40
Gemini
77
40
Claude
86
33
Grok
85

Key Details

Category
Provider Data API
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Ribbon Health
Provider Data API

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.